Hims & Hers Health (NYSE:HIMS) Shares Down 1.8% on Insider Selling

Get Free Report)’s stock price was down 1.8% during mid-day trading on Tuesday after an insider sold shares in the company. The stock traded as low as $55.76 and last traded at $55.86. Approximately 12,367,363 shares traded hands during trading, a decline of 40% from the average daily volume of 20,724,897 shares. The stock had previously closed at $56.86.

Specifically, insider the SEC website.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Citigroup reissued a “sell” rating and set a $30.00 target price (up previously from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. UBS Group reissued a “mixed” rating on shares of Hims & Hers Health in a report on Tuesday, May 6th. Morgan Stanley reduced their target price on Hims & Hers Health from $60.00 to $40.00 and set an “equal weight” rating for the company in a report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Canaccord Genuity Group increased their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $38.00.

Hims & Hers Health Stock Down 3.0%

The firm has a 50-day moving average price of $43.29 and a 200 day moving average price of $37.67. The firm has a market capitalization of $12.35 billion, a PE ratio of 125.35 and a beta of 2.09.

Hims & Hers Health last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to analysts’ expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period last year, the firm earned $0.05 earnings per share. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Farallon Capital Management LLC raised its stake in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. raised its stake in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after buying an additional 2,020,722 shares in the last quarter. Nuveen LLC acquired a new stake in Hims & Hers Health in the first quarter valued at $58,403,000. Finally, Yong Rong HK Asset Management Ltd acquired a new stake in Hims & Hers Health in the fourth quarter valued at $41,104,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.